Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus standard hemoglobin threshold for starting NeoRecormon in chemotherapy-associated anemia in lymphoproliferative malignancies
2006-003727-37Phase 3Active
- Sponsor
- HagaZiekenhuis
- Start
- Jul 2006
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin beta in anaemia (2 arms), sponsored by HagaZiekenhuis. Primary endpoints: Time to treatment success, Red blood cell transfusion requirement overall and 1 more. Started Jul 2006; status: active.
02
Drugs
epoetin beta
03
Conditions
anaemia
Beyond the preview
Go deeper on 2006-003727-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003727-37.